PLoS ONE (Jan 2016)

Bee Venom for the Treatment of Parkinson Disease - A Randomized Controlled Clinical Trial.

  • Andreas Hartmann,
  • Julia Müllner,
  • Niklaus Meier,
  • Helke Hesekamp,
  • Priscilla van Meerbeeck,
  • Marie-Odile Habert,
  • Aurélie Kas,
  • Marie-Laure Tanguy,
  • Merry Mazmanian,
  • Hervé Oya,
  • Nissen Abuaf,
  • Hafida Gaouar,
  • Sabrina Salhi,
  • Fanny Charbonnier-Beaupel,
  • Marie-Hélène Fievet,
  • Damien Galanaud,
  • Sophie Arguillere,
  • Emmanuel Roze,
  • Bertrand Degos,
  • David Grabli,
  • Lucette Lacomblez,
  • Cécile Hubsch,
  • Marie Vidailhet,
  • Anne-Marie Bonnet,
  • Jean-Christophe Corvol,
  • Michael Schüpbach

DOI
https://doi.org/10.1371/journal.pone.0158235
Journal volume & issue
Vol. 11, no. 7
p. e0158235

Abstract

Read online

In the present study, we examined the potential symptomatic and/or disease-modifying effects of monthly bee venom injections compared to placebo in moderatly affected Parkinson disease patients. We conducted a prospective, randomized double-blind study in 40 Parkinson disease patients at Hoehn & Yahr stages 1.5 to 3 who were either assigned to monthly bee venom injections or equivalent volumes of saline (treatment/placebo group: n = 20/20). The primary objective of this study was to assess a potential symptomatic effect of s.c. bee venom injections (100 μg) compared to placebo 11 months after initiation of therapy on United Parkinson’s Disease Rating Scale (UPDRS) III scores in the « off » condition pre-and post-injection at a 60 minute interval. Secondary objectives included the evolution of UPDRS III scores over the study period and [123I]-FP-CIT scans to evaluate disease progression. Finally, safety was assessed by monitoring specific IgE against bee venom and skin tests when necessary. After an 11 month period of monthly administration, bee venom did not significantly decrease UPDRS III scores in the « off » condition. Also, UPDRS III scores over the study course, and nuclear imaging, did not differ significantly between treatment groups. Four patients were excluded during the trial due to positive skin tests but no systemic allergic reaction was recorded. After an initial increase, specific IgE against bee venom decreased in all patients completing the trial. This study did not evidence any clear symptomatic or disease-modifying effects of monthly bee venom injections over an 11 month period compared to placebo using a standard bee venom allergy desensitization protocol in Parkinson disease patients. However, bee venom administration appeared safe in non-allergic subjects. Thus, we suggest that higher administration frequency and possibly higher individual doses of bee venom may reveal its potency in treating Parkinson disease.ClinicalTrials.gov NCT01341431.